StonvexLoading…
StonvexStonvexStonvexPatient Capital Management exited its entire 2.79 million share position in Mattel for approximately $50.9 million during Q1 2026, as the stock has declined 24% over the past year despite the Barbie movie's success. While Q1 2026 net sales grew 4% with strong international performance and Hot Wheels momentum, Barbie gross billings fell 16% and the company faces margin pressures from tariffs and inflation.
Patient Capital Management fully exited its 2.79 million share position in Mattel during Q1 2026, selling for approximately $50.9 million. Despite the blockbuster success of the Barbie movie, Mattel stock has declined 24% over the past year, underperforming the S&P 500. While Q1 net sales rose 4% driven by strong international growth and Hot Wheels momentum, Barbie gross billings fell 16% and margins contracted due to tariffs and inflation pressures. The company is attempting to transition from a toy maker into a broader entertainment and IP company through digital gaming initiatives.
Summary and sentiment are generated by AI for educational purposes. Always verify with the original source before making investment decisions.
Risk warning
Investing in equities carries significant risk, including the potential loss of your entire investment. Volatility, liquidity, geopolitical, and currency risks can all materially affect outcomes. Past performance does not guarantee future results. Nothing on Stonvex is investment advice, a recommendation, or a solicitation to buy or sell any security. Stonvex is not a registered investment advisor (RIA), broker-dealer, or financial planner. You should consult a licensed advisor before making investment decisions and only invest capital you can afford to lose.
© 2026 Stonvex. All rights reserved.
Service not available to residents of: Belarus, China, Cuba, France, Germany, India, Iran, Japan, North Korea, Russia, South Korea, Sudan, Syria. See Terms. You must be 18 years or older to use this service.